Literature DB >> 14644240

Residual triamcinolone acetonide in the macular hole after vitrectomy.

Masaru Takeuchi1, Yoshiaki Katagiri, Masahiko Usui.   

Abstract

PURPOSE: To report a case of vitrectomy using intraocular triamcinolone acetonide (TA), in which TA remained in the macular hole after surgery.
DESIGN: Observational case report.
METHODS: A 60-year-old Japanese man had a Stage II macular hole in the right eye with best-corrected visual acuity of 20/50. A pars plana vitrectomy using TA was performed. Visual acuity and anatomic results were followed up for a period of 8 weeks.
RESULTS: On the sixth postoperative day, residual TA deposition was observed in the macular hole. On the 14th postoperative day, no residual TA was found and the macular hole was successfully closed. The best-corrected visual acuity of the right eye improved to 20/15.
CONCLUSIONS: Residual TA in the macular hole after vitrectomy did not interfere with macular hole repair either anatomically or functionally.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644240     DOI: 10.1016/s0002-9394(03)00674-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Diagnosis and treatment of myopic traction maculopathy.

Authors:  Ping-Bo Ouyang; Xuan-Chu Duan; Xiao-Hua Zhu
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

2.  Dilute triamcinolone-assisted peeling of the internal limiting membrane in cases of diffuse diabetic macular oedema.

Authors:  Remzi Avci; Berrin Avci; Berkant Kaderli
Journal:  Int Ophthalmol       Date:  2006-12-01       Impact factor: 2.031

3.  Use of triamcinolone during vitrectomy surgery to visualize membranes and vitreous.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2008-12

4.  Residual triamcinolone acetonide at macular hole after vitreous surgery.

Authors:  Atul Kumar; Subijay Sinha; Anoop Gupta
Journal:  Indian J Ophthalmol       Date:  2010 May-Jun       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.